These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24340637)

  • 21. Regulation of tissue-engineered products in the European Union: where are we heading?
    Brévignon-Dodin L; Livesey F
    Regen Med; 2006 Sep; 1(5):709-14. PubMed ID: 17465739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering human tissue and regulation: confronting biology and law to bridge the gaps.
    Longley D; Lawford P
    Med Law Int; 2001; 5(2):101-15. PubMed ID: 14696620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory and microbiological safety issues surrounding cell and tissue-engineering products.
    Galbraith DN
    Biotechnol Appl Biochem; 2004 Aug; 40(Pt 1):35-9. PubMed ID: 15270705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health.
    Molzon JA; Giaquinto A; Lindstrom L; Tominaga T; Ward M; Doerr P; Hunt L; Rago L
    Clin Pharmacol Ther; 2011 Apr; 89(4):503-12. PubMed ID: 21326288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ICH: an exclusive club of drug regulatory agencies and drug companies imposing its rules on the rest of the world.
    Prescrire Int; 2010 Aug; 19(108):183-6. PubMed ID: 20939460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New Croatian legislation on tissue banking].
    Busić M
    Acta Med Croatica; 2007 Dec; 61(5):445-7. PubMed ID: 18350803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
    Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
    Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International Conference on Harmonisation; guidance on M4 common technical document; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Oct; 66(200):52634-7. PubMed ID: 12358037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Supervision, administration and standard research related to tissue engineered medical products].
    Xi TF; Chen L; Zhao P
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 Nov; 17(6):480-7. PubMed ID: 14663949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical assessment of the directive on tissue engineering of the European union.
    Trommelmans L; Selling J; Dierickx K
    Tissue Eng; 2007 Apr; 13(4):667-72. PubMed ID: 17253926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A European regulatory pathway for tissue engineering--at last.
    Williams D
    Med Device Technol; 2007 Sep; 18(5):8, 10-1. PubMed ID: 17939364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia.
    Kudrin A
    J Clin Pharmacol; 2009 Mar; 49(3):268-80. PubMed ID: 19168433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
    Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
    Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Creating conditions for the success of the French industrial advanced therapy sector.
    Lirsac PN; Blin O; Magalon J; ; Angot P; de Barbeyrac E; Bilbault P; Bourg E; Damour O; Faure P; Ferry N; Garbil B; Larghero J; Nguon M; Pattou F; Thumelin S; Yates F
    Therapie; 2015; 70(1):69-94. PubMed ID: 25747840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.